BioSpace News Archive

ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company’s first quarter 2022 financial results will be released after market close on Thursday, May 5, 2022.

AmerisourceBergen, a global healthcare company, announces a program designed to help hospitals and health systems launch or optimize home infusion service lines.

Clarus Therapeutics Holdings, Inc. today announced that it has received a notice of allowance from the United States Patent and Trademark Office (USPTO) for claims that cover its oral testosterone replacement product, JATENZO (testosterone undecanoate).

Scilex Holding Company, a nearly 100% majority-owned subsidiary of Sorrento Therapeutics, Inc., announced that Elizabeth Czerepak will join the company as Executive Vice President, Chief Financial Officer and Chief Business Officer, effective May 18, 2022.

XBiotech announced that the French National Agency for the Safety of Medicines and Health Products [L’Agence nationale de sécurité du médicament et des produits de santé ] approved the launch of a multicenter randomized clinical study for XBiotech’s candidate cancer treatment Natrunix in combination with trifluridine/tipiracil for the treatment of colorectal cancer.

CardieX Limited, a global health technology company focused on cardiovascular disease and vascular health disorders, is pleased to announce the appointment of Lesa Musatto to its Board of Directors as a US-based Non-executive Director, effective immediately.

Abbott (NYSE: ABT) today announced U.S. availability of its Amplatzer™ Steerable Delivery Sheath, which is used with the company’s Amplatzer Amulet™ Left Atrial Appendage (LAA) Occluder to treat people with atrial fibrillation (AFib) who are at risk of ischemic stroke.

Harrington Discovery Institute at University Hospitals in Cleveland, Ohio, announced the 2022 class of Harrington Scholar-Innovators.

Harvard University spinout advances a unique complementary metal-oxide-semiconductor -powered drug discovery platform that opens a new dimension in cell-based screening

NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative medical imaging technology company, today announced that its deep-learning medical imaging analytics subsidiary, Nanox.AI, received FDA 510(k) clearance for HealthOST device, an AI software that provides qualitative and quantitative analysis of the spine from CT to support clinicians in the evaluation and assessment of musculoskeletal disease.